A case of gallbladder cancer which completely responded to gemcitabine

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 9, 2010, Pages 1771-1773

  Yoshida, Ryosuke ^a   Matsuda, Tadakazu ^a   Watanabe, Takamasa ^a   Iwadou, Hironori ^a   Hunabiki, Kazumi ^a   Kamikawa, Yasuaki ^a  

^a Tenwakai Matsuda Hospital   (Japan)

Author keywords

Complete response; Gallbladder cancer; Gemcitabine

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER TISSUE; CASE REPORT; CHOLECYSTECTOMY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; FIBROSIS; FOLLOW UP; GALLBLADDER CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MALE; TUMOR VOLUME;

EID: 79960775494     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Nagakawa T, Kayahara M, Ikeda S, et al: Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9(5): 569-575, 2002. (Pubitemid 36305102)
2. Huang P, Chubb S, Hertel LW, et al: Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51 (22): 6110-6117, 1991.
3. Okusaka T, Ishii H, Funakoshi A, et al: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57(5): 647-653, 2006.
4. Ueno H, Okusaka T, Ikeda M. et al: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91(10): 1769-1774, 2004.
5. Furuse J, Okusaka T, Boku N, et al: S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62(5): 849-855, 2008.
6. Penz M, Kornek GV, Raderer M, et al: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12(2): 183-186, 2001.